Building a Robust
and Enduring Pipeline
Pipeline
We are dedicated to advancing innovative therapies with a focused pipeline of potential first-in-class investigational medicines. These are meticulously designed to address critical needs within Huntington’s disease, SCA1, SCA3, Rett Syndrome, and FAD, aiming to transform patient outcomes.
Leadership
Micah Mackison
Mr. Micah Mackison was appointed CEO of Vico Therapeutics in August 2022. Prior to this role, Micah served as Chief Business Officer and Executive Vice President of Strategy and Corporate Development at Locanabio, an RNA-targeted gene therapy company. At Locanabio, he was instrumental in setting strategy, raising capital and helping build an organization focused on genetic neurological diseases. Prior to Locanabio, Micah held several leadership positions in corporate development and strategy. He served as Senior Vice President, Corporate Development and Strategy at Assembly Biosciences where he led business development efforts. Previously, Micah served as Head of Corporate Strategy and Senior Director, New Ventures at H. Lundbeck A/S, where he was focused on neuroscience. Prior to Lundbeck’s acquisition, he was Director, Corporate Development and M&A at Ovation Pharmaceuticals, a neuroscience-focused company that launched the first product for Huntington’s disease.
Earlier in his career, Micah held financial roles at Eli Lilly and Pfizer. He earned a B.S. in Finance from the Kelley School of Business at Indiana University.
